Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Trading 03-03 15:15:22 EST

27.94

-0.16

-0.57%

High28.24	Low26.94	Vol3.34M
Open27.34	D1 Closing28.10	Amplitude4.62%
Mkt Cap20.00B	Tradable Cap13.05B	Total Shares715.70M
T/O91.89M	T/O Rate0.72%	Tradable Shares467.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":27.94,"timestamp":1772568922160,"preClose":28.1,"halted":0,"volume":3340409,"delay":0,"changeRate":-0.005693950177935948,"floatShares":467000000,"shares":715701137,"eps":-1.173433,"marketStatus":"Trading","change":-0.16,"latestTime":"03-03 15:15:22 EST","open":27.34,"high":28.24,"low":26.942,"amount":91889236.787011,"amplitude":0.046192,"askPrice":27.94,"askSize":14,"bidPrice":27.93,"bidSize":702,"shortable":3,"etf":0,"ttmEps":-1.173433,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772571600000},"marketStatusCode":2,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":28.1,"preHourTrading":{"tag":"盘前","latestPrice":27.57,"preClose":28.1,"latestTime":"09:28 EST","volume":2365,"amount":65546.85005,"timestamp":1772548082264,"change":-0.53,"changeRate":-0.018861,"amplitude":0.023488},"postHourTrading":{"tag":"盘后","latestPrice":28.5,"preClose":28.1,"latestTime":"19:59 EST","volume":65319,"amount":1835810.88,"timestamp":1772499554512,"change":0.4,"changeRate":0.014235,"amplitude":0.014235},"volumeRatio":0.855428,"impliedVol":0.3934,"impliedVolPercentile":0.6534},"requestUrl":"/m/hq/s/ROIV/wiki","defaultTab":"wiki","newsList":[{"id":"2616342826","title":"Priovant wins FDA Priority Review for brepocitinib dermatomyositis NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342826","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342826?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539253,"startTime":"0","endTime":"0","summary":"Priovant Therapeutics, an affiliate of Roivant Sciences Ltd., said the FDA has accepted its new drug application for brepocitinib to treat dermatomyositis and granted Priority Review. The FDA set a PDUFA target action date in the third quarter of 2026, and Priovant expects a U.S. launch at the end of September 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL1npYzn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","SG9999014013.SGD","BK4112","ROIV","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4007","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","LU2210149790.SGD","BK4588","NDAQ"],"gpt_icon":0},{"id":"2616344439","title":"Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616344439?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA2DS9Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2616342877","title":"Roivant Sciences Ltd - FDA Assigns Pdufa Date Q3 2026, Launch Expected September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342877?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA2DS9Z6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2613752990","title":"Roivant Sciences President and Vant Chair Frank Torti Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2613752990","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613752990?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:40","pubTimestamp":1771897249,"startTime":"0","endTime":"0","summary":"Frank Torti, President and Vant Chair of Roivant Sciences Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL5Db3wk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences President and Vant Chair Frank Torti Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2612427295","title":"Roivant President and Immunovant CEO Eric Venker Disposes of Roivant Sciences Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612427295","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612427295?lang=en_us&edition=fundamental","pubTime":"2026-02-19 06:57","pubTimestamp":1771455468,"startTime":"0","endTime":"0","summary":"Eric Venker, President & Immunovant CEO, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8Yrs1h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4588","IMVT","BK4585","BK4007"],"gpt_icon":0},{"id":"2611197863","title":"Roivant Sciences Director Keith S. Manchester Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611197863","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611197863?lang=en_us&edition=fundamental","pubTime":"2026-02-14 10:02","pubTimestamp":1771034574,"startTime":"0","endTime":"0","summary":"Keith S. Manchester, Director, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260214:nNDL4xnGNK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2611192267","title":"QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611192267","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611192267?lang=en_us&edition=fundamental","pubTime":"2026-02-14 09:46","pubTimestamp":1771033596,"startTime":"0","endTime":"0","summary":"QVT Financial LP has reported a disposal of common shares of Roivant Sciences Ltd. The transaction involved the sale of 425,000 shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260214:nNDL3nBvNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2610673249","title":"Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2610673249","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610673249?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:54","pubTimestamp":1770850442,"startTime":"0","endTime":"0","summary":"Mayukh Sukhatme, President & Chief Investment Officer of Roivant Sciences Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbz53gH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2610047641","title":"Roivant Sciences price target raised to $35 from $26 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2610047641","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610047641?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:36","pubTimestamp":1770723403,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Roivant Sciences (ROIV) to $35 from $26 and keeps a Buy rating on the shares. The firm views the company’s P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-35-from-26-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-35-from-26-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2610043659","title":"Roivant Sciences Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2610043659","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610043659?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:56","pubTimestamp":1770648960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 09:56 ET (14:56 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2610508545","title":"Roivant Sciences price target raised to $26 from $22 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2610508545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610508545?lang=en_us&edition=fundamental","pubTime":"2026-02-09 04:45","pubTimestamp":1770583514,"startTime":"0","endTime":"0","summary":"BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $22 and keeps a Neutral rating on the shares post the f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-26-from-22-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-26-from-22-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2610778075","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610778075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610778075?lang=en_us&edition=fundamental","pubTime":"2026-02-09 01:20","pubTimestamp":1770571217,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immunovant (IMVT – Research Report) and Roivant Sciences (ROIV – ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-immunovant-imvt-and-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-immunovant-imvt-and-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","ROIV","LU0029874061.USD","HCSG","BK4139","LU0128526141.USD","BK4588","BK4581","LABU","BK4585","BK4007","IMVT","BK4137","XLV"],"gpt_icon":0},{"id":"2609578298","title":"Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2609578298","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609578298?lang=en_us&edition=fundamental","pubTime":"2026-02-08 11:11","pubTimestamp":1770520284,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) just posted its Q3 2026 numbers with total revenue of about US$2.0 million and a basic EPS loss of US$0.38, alongside a net income loss, excluding extra items, of US$265.9 million. The company has seen quarterly revenue move from US$9.0 million in Q3 2025 to US$2.0 million in Q3 2026, while basic EPS shifted from a loss of US$0.22 to a loss of US$0.38 over the same period. This sets the scene for investors to weigh near term revenue scale against the size of ongoing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ROIV","BK4007","BK4112"],"gpt_icon":0},{"id":"2609454901","title":"Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2609454901","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609454901?lang=en_us&edition=fundamental","pubTime":"2026-02-07 10:16","pubTimestamp":1770430573,"startTime":"0","endTime":"0","summary":"Roivant Sciences reported third-quarter 2025 results showing sales of US$2.00 million and a net loss of US$265.89 million, while subsidiaries Priovant and Pulmovant advanced key Phase 2 programs in rare inflammatory and pulmonary diseases.\nTogether with positive Phase 2 brepocitinib data in cutaneous sarcoidosis and rapid enrollment of mosliciguat’s PHocus trial, Roivant’s pipeline activity is increasingly central to its story despite widened losses.\nWe’ll now examine how Roivant’s progress...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-194-after-advancing-phase-2-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-194-after-advancing-phase-2-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2609514334","title":"Analysts Are Bullish on These Healthcare Stocks: Knight Therapeutics (KHTRF), Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609514334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609514334?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:30","pubTimestamp":1770413419,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Knight Therapeutics (KHTRF – Research Report) and Ro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-knight-therapeutics-khtrf-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-knight-therapeutics-khtrf-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","LABU","BK4112","BK4588","LU0029874061.USD","XBI","LU0128526141.USD","BK4139","BK4581","ROIV","BK4007","KHTRF"],"gpt_icon":0},{"id":"2609151275","title":"BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina","url":"https://stock-news.laohu8.com/highlight/detail?id=2609151275","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609151275?lang=en_us&edition=fundamental","pubTime":"2026-02-07 02:45","pubTimestamp":1770403531,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","NWSA","BIIB","EQT","NSC","MAXN","AVY","MGM","UI","NWL","HUBG","THAR","AGMB","CDE","PHM","VG","PM","DOCS","HL","CNX","LEN","OFRM","NEM","EXE","MCHP","HOYY","PLRZ","TGTX","KBH","COTY","NVR","RIOT","SGP","UAA","GWW","MOH","FTNT","ROIV","PIPR","PAA","AZYY"],"gpt_icon":1},{"id":"2609903245","title":"Roivant Sciences Up Over 17%, on Track for Record High Close -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2609903245","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609903245?lang=en_us&edition=fundamental","pubTime":"2026-02-07 00:04","pubTimestamp":1770393840,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  is currently at $24.77, up $3.63 or 17.16%. --On pace for largest percent increase since Sept. 26, 2023, when it rose 21.55%. --Up 127.43% from 52 weeks ago , when it closed at $10.89. --Up 172.77% from its 52-week closing low of $9.08 on April 8, 2025. --Traded as high as $25.49; new all-time intraday high . --Up 20.58% at today's intraday high; largest intraday percent increase since Sept. 26, 2023, when it rose as much as 25.66%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2609859779","title":"BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison","url":"https://stock-news.laohu8.com/highlight/detail?id=2609859779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609859779?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:56","pubTimestamp":1770393385,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery DennisonEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQT","AMZZ","PM","09399","09799","HOYY","AVY","CNX","UI","NWSA","ROIV","VG","EXE","OFRM","GWW","CDE","HODU","COTY","CG","3LMI.UK","PLRZ","TGTX","THAR","NEM","AMZD","DOCS","MOH","BIIB","MGM","ROBN","RIOT","MCHP","NSC","HUBG","UAA","FTNT","07399","PAA","HL","MAXN","NWL"],"gpt_icon":1},{"id":"2609920345","title":"Roivant Sciences rises 16.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609920345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609920345?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:06","pubTimestamp":1770390419,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) is up 16.9%, or $3.57 to $24.71. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-rises-16-9-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-rises-16-9-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"1168089334","title":"Stock Track | Roivant Sciences Soars 19.68% Intraday on Positive Phase 2 Results for Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1168089334","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168089334?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:56","pubTimestamp":1770389804,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) experienced a significant intraday surge of 19.68% on Friday. The sharp upward movement follows the release of encouraging clinical trial data from one of its subsidiary...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ROIV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.2997},{"period":"3month","weight":0.398},{"period":"6month","weight":1.2319},{"period":"1year","weight":1.6164},{"period":"ytd","weight":0.2949}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.085297},{"month":4,"riseRate":0.8,"avgChangeRate":0.019894},{"month":5,"riseRate":0.4,"avgChangeRate":0.032328},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction